224 related articles for article (PubMed ID: 30797859)
21. A high rate of polymerization during synthesis of mouse mammary tumor virus DNA alleviates hypermutation by APOBEC3 proteins.
Hagen B; Kraase M; Indikova I; Indik S
PLoS Pathog; 2019 Feb; 15(2):e1007533. PubMed ID: 30768644
[TBL] [Abstract][Full Text] [Related]
22. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
23. Deamination-independent restriction of LINE-1 retrotransposition by APOBEC3H.
Feng Y; Goubran MH; Follack TB; Chelico L
Sci Rep; 2017 Sep; 7(1):10881. PubMed ID: 28883657
[TBL] [Abstract][Full Text] [Related]
24. Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.
Kobayashi T; Koizumi Y; Takeuchi JS; Misawa N; Kimura Y; Morita S; Aihara K; Koyanagi Y; Iwami S; Sato K
J Virol; 2014 May; 88(10):5881-7. PubMed ID: 24623435
[TBL] [Abstract][Full Text] [Related]
25. Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription.
Jin SY; Choi HY; Kim HS; Jung YT
Arch Virol; 2018 Jul; 163(7):1907-1914. PubMed ID: 29610985
[TBL] [Abstract][Full Text] [Related]
26. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.
Meissner ME; Willkomm NA; Lucas J; Arndt WG; Aitken SF; Julik EJ; Baliga S; Mansky LM
J Mol Biol; 2022 Jan; 434(2):167355. PubMed ID: 34774569
[TBL] [Abstract][Full Text] [Related]
27. Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription.
Nair S; Zlotnick A
J Virol; 2018 May; 92(10):. PubMed ID: 29491156
[TBL] [Abstract][Full Text] [Related]
28. Biochemical Basis of APOBEC3 Deoxycytidine Deaminase Activity on Diverse DNA Substrates.
Adolph MB; Love RP; Chelico L
ACS Infect Dis; 2018 Mar; 4(3):224-238. PubMed ID: 29347817
[TBL] [Abstract][Full Text] [Related]
29. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
30. Different antiviral activities of natural APOBEC3C, APOBEC3G, and APOBEC3H variants against hepatitis B virus.
Kanagaraj A; Sakamoto N; Que L; Li Y; Mohiuddin M; Koura M; Wakae K; Kurachi M; Muramatsu M; Kitamura K
Biochem Biophys Res Commun; 2019 Oct; 518(1):26-31. PubMed ID: 31400856
[TBL] [Abstract][Full Text] [Related]
31. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
Schumacher AJ; Haché G; Macduff DA; Brown WL; Harris RS
J Virol; 2008 Mar; 82(6):2652-60. PubMed ID: 18184715
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G.
Bouzidi MS; Caval V; Suspène R; Hallez C; Pineau P; Wain-Hobson S; Vartanian JP
J Mol Biol; 2016 Aug; 428(17):3514-28. PubMed ID: 27289067
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
34. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
Albin JS; Harris RS
Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
[TBL] [Abstract][Full Text] [Related]
36. Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.
Knoepfel SA; Salisch NC; Huelsmann PM; Rauch P; Walter H; Metzner KJ
J Virol; 2008 Jul; 82(13):6536-45. PubMed ID: 18448538
[TBL] [Abstract][Full Text] [Related]
37. Molecular Interactions of a DNA Modifying Enzyme APOBEC3F Catalytic Domain with a Single-Stranded DNA.
Fang Y; Xiao X; Li SX; Wolfe A; Chen XS
J Mol Biol; 2018 Jan; 430(1):87-101. PubMed ID: 29191651
[TBL] [Abstract][Full Text] [Related]
38. A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.
Zhou T; Han Y; Dang Y; Wang X; Zheng YH
Retrovirology; 2009 Apr; 6():31. PubMed ID: 19344514
[TBL] [Abstract][Full Text] [Related]
39. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.
Jaguva Vasudevan AA; Hofmann H; Willbold D; Häussinger D; Koenig BW; Münk C
J Mol Biol; 2017 Apr; 429(8):1171-1191. PubMed ID: 28315663
[TBL] [Abstract][Full Text] [Related]
40. [Recent advances in the study of mechanism of APOBEC3G against virus].
Zhu YP; Jiang JD; Peng ZG
Yao Xue Xue Bao; 2014 Jan; 49(1):30-6. PubMed ID: 24783502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
